150 related articles for article (PubMed ID: 37002660)
21. SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J; Brace EJ; Sasaki Y; DiAntonio A; Milbrandt J
Science; 2015 Apr; 348(6233):453-7. PubMed ID: 25908823
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.
Bosanac T; Hughes RO; Engber T; Devraj R; Brearley A; Danker K; Young K; Kopatz J; Hermann M; Berthemy A; Boyce S; Bentley J; Krauss R
Brain; 2021 Nov; 144(10):3226-3238. PubMed ID: 33964142
[TBL] [Abstract][Full Text] [Related]
23. Neurotoxin-mediated potent activation of the axon degeneration regulator SARM1.
Loreto A; Angeletti C; Gu W; Osborne A; Nieuwenhuis B; Gilley J; Merlini E; Arthur-Farraj P; Amici A; Luo Z; Hartley-Tassell L; Ve T; Desrochers LM; Wang Q; Kobe B; Orsomando G; Coleman MP
Elife; 2021 Dec; 10():. PubMed ID: 34870595
[TBL] [Abstract][Full Text] [Related]
24. Palmitoylation enables MAPK-dependent proteostasis of axon survival factors.
Summers DW; Milbrandt J; DiAntonio A
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8746-E8754. PubMed ID: 30150401
[TBL] [Abstract][Full Text] [Related]
25. DLK Activation Synergizes with Mitochondrial Dysfunction to Downregulate Axon Survival Factors and Promote SARM1-Dependent Axon Degeneration.
Summers DW; Frey E; Walker LJ; Milbrandt J; DiAntonio A
Mol Neurobiol; 2020 Feb; 57(2):1146-1158. PubMed ID: 31696428
[TBL] [Abstract][Full Text] [Related]
26. A phase transition reduces the threshold for nicotinamide mononucleotide-based activation of SARM1, an NAD(P) hydrolase, to physiologically relevant levels.
Icso JD; Thompson PR
J Biol Chem; 2023 Nov; 299(11):105284. PubMed ID: 37742918
[TBL] [Abstract][Full Text] [Related]
27. NAD
Cao Y; Wang Y; Yang J
Cell Insight; 2022 Apr; 1(2):100019. PubMed ID: 37193131
[TBL] [Abstract][Full Text] [Related]
28. NMNAT2 supports vesicular glycolysis via NAD homeostasis to fuel fast axonal transport.
Yang S; Niou ZX; Enriquez A; LaMar J; Huang JY; Ling K; Jafar-Nejad P; Gilley J; Coleman MP; Tennessen JM; Rangaraju V; Lu HC
Mol Neurodegener; 2024 Jan; 19(1):13. PubMed ID: 38282024
[TBL] [Abstract][Full Text] [Related]
29. Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.
Shi Y; Kerry PS; Nanson JD; Bosanac T; Sasaki Y; Krauss R; Saikot FK; Adams SE; Mosaiab T; Masic V; Mao X; Rose F; Vasquez E; Furrer M; Cunnea K; Brearley A; Gu W; Luo Z; Brillault L; Landsberg MJ; DiAntonio A; Kobe B; Milbrandt J; Hughes RO; Ve T
Mol Cell; 2022 May; 82(9):1643-1659.e10. PubMed ID: 35334231
[TBL] [Abstract][Full Text] [Related]
30. Axon degeneration: mechanistic insights lead to therapeutic opportunities for the prevention and treatment of peripheral neuropathy.
DiAntonio A
Pain; 2019 May; 160 Suppl 1(Suppl 1):S17-S22. PubMed ID: 31008845
[TBL] [Abstract][Full Text] [Related]
31. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.
Summers DW; Gibson DA; DiAntonio A; Milbrandt J
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6271-E6280. PubMed ID: 27671644
[TBL] [Abstract][Full Text] [Related]
32. Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1.
Bratkowski M; Xie T; Thayer DA; Lad S; Mathur P; Yang YS; Danko G; Burdett TC; Danao J; Cantor A; Kozak JA; Brown SP; Bai X; Sambashivan S
Cell Rep; 2020 Aug; 32(5):107999. PubMed ID: 32755591
[TBL] [Abstract][Full Text] [Related]
33. Macrophage depletion blocks congenital SARM1-dependent neuropathy.
Dingwall CB; Strickland A; Yum SW; Yim AK; Zhu J; Wang PL; Yamada Y; Schmidt RE; Sasaki Y; Bloom AJ; DiAntonio A; Milbrandt J
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36287209
[TBL] [Abstract][Full Text] [Related]
34. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration.
Gould SA; Gilley J; Ling K; Jafar-Nejad P; Rigo F; Coleman M
Cell Rep; 2021 Dec; 37(11):110108. PubMed ID: 34910914
[TBL] [Abstract][Full Text] [Related]
35. SARM1 participates in axonal degeneration and mitochondrial dysfunction in prion disease.
Lai MY; Li J; Zhang XX; Wu W; Li ZP; Sun ZX; Zhao MY; Yang DM; Wang DD; Li W; Zhao DM; Zhou XM; Yang LF
Neural Regen Res; 2022 Oct; 17(10):2293-2299. PubMed ID: 35259852
[TBL] [Abstract][Full Text] [Related]
36. NMNAT2 supports vesicular glycolysis via NAD homeostasis to fuel fast axonal transport.
Yang S; Niou ZX; Enriquez A; LaMar J; Huang JY; Ling K; Jafar-Nejad P; Gilley J; Coleman MP; Tennessen JM; Rangaraju V; Lu HC
Res Sq; 2023 May; ():. PubMed ID: 37292715
[TBL] [Abstract][Full Text] [Related]
37. SARM1 signaling mechanisms in the injured nervous system.
Sambashivan S; Freeman MR
Curr Opin Neurobiol; 2021 Aug; 69():247-255. PubMed ID: 34175654
[TBL] [Abstract][Full Text] [Related]
38. Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca(2+) Influx but Only Modestly Influenced by Mitochondria.
Loreto A; Di Stefano M; Gering M; Conforti L
Cell Rep; 2015 Dec; 13(11):2539-2552. PubMed ID: 26686637
[TBL] [Abstract][Full Text] [Related]
39. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
40. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD
Sasaki Y; Nakagawa T; Mao X; DiAntonio A; Milbrandt J
Elife; 2016 Oct; 5():. PubMed ID: 27735788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
